Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anastrozole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    117 result(s) found for: Anastrozole. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2020-003960-22 Sponsor Protocol Number: WOO2 Start Date*: 2021-03-15
    Sponsor Name:Medical University of Innsbruck
    Full Title: Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer
    Medical condition: (ER+) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000112-21 Sponsor Protocol Number: MESI-STRAT-WOO Start Date*: 2018-09-03
    Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medizinische Fakultät, vertreten durch das Universitätsklinikum Heidelberg
    Full Title: Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer
    Medical condition: (ER+) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006326-24 Sponsor Protocol Number: D699BC00001 Start Date*: 2012-11-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg with Anastrozole (ARIMIDEX) 1 mg as Hormonal Treat...
    Medical condition: hormone receptor positive breast cancer, hormone naive, breast, cancer, neoplasm breast cancer, metastatic, tumour, neoplasm
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) CZ (Completed) SK (Completed) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005081-17 Sponsor Protocol Number: ARV-471-BC-201 Start Date*: 2023-01-20
    Sponsor Name:Arvinas Estrogen Receptor, Inc. (Arvinas)
    Full Title: An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting
    Medical condition: Post-menopausal women with ER+ HER2– breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003530-13 Sponsor Protocol Number: 18072011 Start Date*: 2011-12-20
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000320-14 Sponsor Protocol Number: D6997L00002 (9238SW0001) Start Date*: 2006-03-29
    Sponsor Name:AstraZeneca oy
    Full Title: Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women ...
    Medical condition: Hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed) PT (Completed) IS (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000454-32 Sponsor Protocol Number: C/23/2011 Start Date*: 2012-01-17
    Sponsor Name:Imperial College London
    Full Title: A single arm phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients ...
    Medical condition: ER Positive Progressing Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000384-10 Sponsor Protocol Number: D6873C00047 Start Date*: 2005-03-15
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocio...
    Medical condition: testotoxicosis (familial male-limited gonadotropin-independent precocious puberty)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10063654 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002276-12 Sponsor Protocol Number: D8532C00001 Start Date*: 2021-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Recepto...
    Medical condition: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012934-63 Sponsor Protocol Number: D0102C00004 Start Date*: 2009-10-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-men...
    Medical condition: Locally Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001180-77 Sponsor Protocol Number: D6873C00047 Start Date*: 2012-03-07
    Sponsor Name:AstraZeneca
    Full Title: An open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocio...
    Medical condition: testotoxicosis (precocious puberty)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10063654 Testotoxicosis PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-005486-75 Sponsor Protocol Number: I3Y-MC-JPBY Start Date*: 2015-07-24
    Sponsor Name:Lilly S.A.
    Full Title: neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Mo...
    Medical condition: Postmenopausal Women with Hormone Receptor Postive, HER2 Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002868-28 Sponsor Protocol Number: D6995C00006 Start Date*: 2005-12-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Open-Label, Parallel-Group, Multi-centre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as First Line H...
    Medical condition: Hormone Receptor Positive Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004120-11 Sponsor Protocol Number: BOOG2013-06 Start Date*: 2014-03-17
    Sponsor Name:VU University Medical Center
    Full Title: PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatmen...
    Medical condition: Hormone receptor-positive advanced metastatic breast cancer in postmenopausal patients who have progressed on anastrozole or letrozole.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003992-35 Sponsor Protocol Number: MREC02/8/71 Start Date*: 2009-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.
    Medical condition: Ductal carcinoma in situ
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10013806 Ductal carcinoma in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001007-16 Sponsor Protocol Number: WO42133 Start Date*: 2020-10-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE II, NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH ANASTROZOLE PLUS PALBOCI...
    Medical condition: Estrogen Receptor (ER)-Positive and HER2-Negative Untreated Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001334-34 Sponsor Protocol Number: CA209-7A8 Start Date*: 2020-12-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer >= 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole
    Medical condition: ER+/HER2- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001893-28 Sponsor Protocol Number: 30-04 Start Date*: 2005-11-18
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer
    Medical condition: Post-menopausal women, histologically or cytologically confirmed, receptor-positive, adequately excised, primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005090-53 Sponsor Protocol Number: BAY98-7196/15832 Start Date*: 2014-09-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, double-dummy, parallel- group, multi-center phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038604 - Reproductive system and breast disorders 10014788 Endometriosis related pain LLT
    18.1 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed) DK (Completed) AT (Completed) BE (Completed) NL (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000962-11 Sponsor Protocol Number: PM0259CA217B0 Start Date*: 2005-03-01
    Sponsor Name:Pierre Fabre Medicament represented by IRPF
    Full Title: Phase II Study of Navelbine oral and Arimidex as neo-adjuvant treatment in post-menopausal women with locally advanced breast carcinoma
    Medical condition: Neo-Adjuvant Treatment in Post-menopausal women with locally advanced breast carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:11:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA